![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Cilta-cel是一种针对BCMA的CAR-T疗法,用于多发性骨髓瘤患者
Sundar Jagannath1, Carolyn C Jackson2, Jordan M Schecter2
1Multiple Myeloma Division, Tisch Cancer Institute, Mount Sinai Medical Center New York, New York, NY, USA.
Expert opinion on biological therapy
|May 13, 2024
概括
在复发性/耐药性多发性骨髓瘤中,Ciltacabtagene autoleucel (cilta-cel) 显示出显著的疗效,提供了改善的无进展生存率和高响应率. 进一步的试验探索其作为多发性骨髓瘤前线治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- Ciltacabtagene autoleucel (cilta-cel) 是一种针对BCMA的CAR-T疗法,已批准用于复发性/耐药性多发性骨髓瘤 (RRMM) 患者,此前已接受特定治疗.
- 目前RRMM的治疗领域包括蛋白酶体抑制剂,免疫调节药物和莱纳利多米德,对更有效的治疗方法的需求尚未得到满足.
研究的目的:
- 审查在重度预处理的RRMM和早期疗法中对cilta-cel的长期疗效和安全数据.
- 讨论cilta-cel作为移植资格和不符合条件的多发性骨髓瘤患者的前线治疗的理由和正在进行的调查.
主要方法:
- 从临床试验LEGEND-2,CARTITUDE-1和CARTITUDE-4评估RRMM中的cilta-cel的长期数据的分析.
- 与前 1-3 个治疗线 (LOT) 患者的标准疗法进行基细胞结局的比较.
- 审查正在进行的试验 (CARTITUDE-5,CARTITUDE-6) 评估前线纤维细胞治疗.
主要成果:
- 观察到高响应率:在CARTITUDE-1中98%和在CARTITUDE-4中接近100%.
- 在重度预治疗的RRMM患者中,无进展生存时间 (PFS) 的中位数为34.9个月 (CARTITUDE-1).
- 显著 74% 的相对风险降低进展/死亡与标准护理相比,在患有 1-3 个先前的 LOT (CARTITUDE-4) 的患者中,安全性可控.
结论:
- 包括cilta-cel在内的CAR-T疗法显示出潜在的潜力,可以显著改善多发性骨髓瘤患者在各种治疗线的治疗结果.
- Cilta-cel已经建立了一个新的疗效基准,并且可能成为RRMM的第一线治疗后的关键治疗选择.
- 对细胞治疗的前线调查有望优化治疗策略,并可能实现治疗多发性骨髓瘤.
关键词:
B细胞成熟抗原 (BCMA) 是一种仿制抗原受体 (CAR) -T细胞疗法基尔塔卡巴泰基因自细胞 (基尔塔细胞)这是一种耐火的lenalidomide.多发性骨髓瘤是一种多发性骨髓瘤.新诊断的多发性骨髓瘤没有进展的生存率.复发性/耐药性多发性髓瘤更多相关视频
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
493
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.3K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Tumor Immunotherapy
518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518